Prostate Specific Antigen (PSA) Testing Market to reach 9,701.66 Million by 2030, emerging at a CAGR of 11.2% and forecast 2023-2030
Prostate Specific Antigen (PSA) Testing Market
Overview
The Prostate
Specific Antigen (PSA) Testing Market
was valued at USD 4,166.48 Million in 2022 and is projected to reach around USD
9,701.66 Million by 2030, reflecting a Compound Annual Growth Rate (CAGR) of
over 11.2%.
The PSA testing market is experiencing
significant growth, driven by factors like rising awareness of prostate cancer
and increasing geriatric population.
Prostate Specific Antigen (PSA) Testing Market
Drivers
Several factors are propelling the
growth of the PSA testing market:
Rising awareness of prostate cancer:
Public health initiatives and educational campaigns are increasing awareness of
prostate cancer, leading to a greater demand for PSA testing as a screening
tool.
Aging population: The global
population is aging, with a growing number of men reaching the age group most
susceptible to prostate cancer. This demographic shift fuels the demand for PSA
testing.
Technological advancements:
Advancements in PSA testing technology, such as more sensitive assays, are
improving the accuracy of early detection.
Government initiatives: Government
healthcare programs promoting early cancer detection can significantly
influence Prostate
Specific Antigen (PSA) Testing Market Growth.
Prostate Specific Antigen (PSA) Testing Market
Key Players
The PSA testing market is moderately
competitive with a presence of established players and emerging companies. Some
key players include:
Bio-Rad Laboratories, Inc., AdvaCare
Pharma, Beckman Coulter, Inc., Proteomedix, Fujirebio (H.U. Group), GE
HealthCare, Abcam plc, Lomina AG, BioReference Health, LLC (OPKO Health, Inc.),
Laboratory Corporation of America Holdings, and Hanzhou Testsea biotechnology
co., LTD.
Prostate Specific Antigen (PSA) Testing Market
Segmentation
By Test Type:
Preliminary Tests and Confirmatory Tests
By End User:
Hospital, Cancer Research Institutes, Diagnostic Laboratory, Ambulatory
Surgical Centers, and Others
By Region:
North America, Europe, Asia-Pacific, Latin America, and Middle East &
Africa
Prostate Specific Antigen (PSA) Testing Market
Regional Analysis
The PSA testing market is
geographically segmented into North America, Europe, Asia Pacific, Latin
America, and the Middle East & Africa. North America currently dominates
the market due to high healthcare spending and established screening programs.
However, the Asia Pacific region is
expected to witness the fastest growth due to a rising aging population and increasing
healthcare expenditure.
Contact us:
Consegic
Business intelligence Pvt Ltd.
Contact no: (US) (505) 715-4344
Email: sales@consegicbusinessintelligence.com
Comments
Post a Comment